| Autor: |
C.D. Price, D. Mangar, E.M. Camporesi, D.K.A. Haas, N.S. El-Badri, R.E. Chaparro |
| Rok vydání: |
2008 |
| Předmět: |
|
| Zdroj: |
The Open Hematology Journal. 2:62-66 |
| ISSN: |
1874-2769 |
| DOI: |
10.2174/1874276900802010062 |
| Popis: |
Cerebral blood flow (CBF) is tightly regulated to meet metabolic demands, and it increases during hemodilu- tion as arterial oxygen content (CaO2) falls. Oxygent® is a perfluorocarbon (PFC) emulsion that has a high capacity to dissolve oxygen and can thus increase CaO2 in patients breathing supplemental oxygen. PFCs have shown excellent oxy- gen therapeutic value in both phase II and phase III clinical trials. However, the effects of Oxygent® on CBF in hemodilu- tion are unknown. We performed this study to investigate how Oxygent® alters CBF in rats undergoing stepwise iso- volumetric hemodilution under isoflurane anesthesia with 100% oxygen ventilation. In vivo Laser Doppler Flow (LDF) probes measured CBF as blood was gradually replaced with equal volumes of either 5%Albumin (controls) or (1:1) PFC and Albumin. Hematocrit and blood gases were measured and CaO2 calculated after each dilution. Target values were to achieve a hematocrit value of 10% and fluorocrit between 7.5-10%. We compared CBF in the Oxygent® vs. control group at decreasing levels of hematocrit and CaO2 with repeated t-tests. At hematocrits less than 15%, CBF rate approached baseline in the Oxygent® group, and was lower than the control group (p = 0.004). At maximal hemodilution, Oxygent® treated rats also showed higher PaO2 (p < 0.001) and required lower phenylephrine infusion rates to maintain blood pres- sure (p = 0.002). These data support that administration of Oxygent® improves tissue oxygenation during hemodilution. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
